| abstract |
The invention relates to a new medical use of statins in the treatment of diseases responsive to the modulation of P2Y purinergic receptors. More specifically, the invention relates to 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, commonly referred to as statins, for use in the treatment of diseases whose etiology and / or course is associated with the modulation of P2Y receptors, i.e. for modulation of the P2Y purinergic receptor. |